Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Deanna M Mudie"'
Autor:
Khaled Heissam, Nichola Abrehart, Caroline L Hoad, Jeff Wright, Alex Menys, Kathryn Murray, Paul M Glover, Geoffrey Hebbard, Penny A Gowland, Jason Baker, William L Hasler, Robin C Spiller, Maura Corsetti, James G Brasseur, Bart Hens, Kerby Shedden, Joseph Dickens, Deanna M Mudie, Greg E Amidon, Gordon L Amidon, Luca Marciani
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0241441 (2020)
ObjectiveThe gastrointestinal environment in which drug products need to disintegrate before the drug can dissolve and be absorbed has not been studied in detail due to limitations, especially invasiveness of existing techniques. Minimal in vivo data
Externí odkaz:
https://doaj.org/article/8b870100c3494f05b33becca50d1d77a
Autor:
Deanna M. Mudie, Aaron M. Stewart, Jesus A. Rosales, Molly S. Adam, Michael M. Morgen, David T. Vodak
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2059 (2021)
The authors wish to make the following corrections to this paper [...]
Externí odkaz:
https://doaj.org/article/17b85916e53649d7995967b75c1488f8
Autor:
Deanna M. Mudie, Aaron M. Stewart, Jesus A. Rosales, Molly S. Adam, Michael M. Morgen, David T. Vodak
Publikováno v:
Pharmaceutics, Vol 13, Iss 8, p 1257 (2021)
Amorphous solid dispersion (ASD) dosage forms can improve the oral bioavailability of poorly water-soluble drugs, enabling the commercialization of new chemical entities and improving the efficacy and patient compliance of existing drugs. However, th
Externí odkaz:
https://doaj.org/article/184cec856c934b98b8bbbecf586d8fd1
Autor:
Deanna M. Mudie, Aaron M. Stewart, Jesus A. Rosales, Nishant Biswas, Molly S. Adam, Adam Smith, Christopher D. Craig, Michael M. Morgen, David T. Vodak
Publikováno v:
Pharmaceutics, Vol 13, Iss 4, p 557 (2021)
Calquence® (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated
Externí odkaz:
https://doaj.org/article/881f3a4a898c49bfb5e5f8d977530edb
Autor:
Deanna M. Mudie
Publikováno v:
Molecular Pharmaceutics. 20:4-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64ea85be935ce000f514874dc9fa40c7
https://doi.org/10.1021/acs.molpharmaceut.2c01019
https://doi.org/10.1021/acs.molpharmaceut.2c01019
Autor:
Gordon L. Amidon, Jozef Al-Gousous, Deanna M. Mudie, Gregory E. Amidon, Robert M. Ziff, Niloufar Salehi
Publikováno v:
Molecular Pharmaceutics. 17:3870-3884
Dissolution is a crucial process for the oral delivery of drug products. Before being absorbed through epithelial cell membranes to reach the systemic circulation, drugs must first dissolve in the human gastrointestinal (GI) tract. In vivo and in vit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d803f14a76ac89b4e9ce67c7355fc4b6
https://doi.org/10.1021/acs.molpharmaceut.0c00614
https://doi.org/10.1021/acs.molpharmaceut.0c00614
Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole; In Vivo and In Vitro Assessment
Autor:
John M. Baumann, Aaron M. Stewart, Timothy J. Brodeur, Michael M. Morgen, Nishant Biswas, Adam J. Smith, Kimberly B. Shepard, Deanna M. Mudie, David T. Vodak
Publikováno v:
Molecular Pharmaceutics. 17:4463-4472
Amorphous solid dispersions (ASDs) can increase the bioavailability of drugs with poor aqueous solubility. However, concentration-sustaining dispersion polymers (CSPs) incorporated in ASDs can result in low drug loading and, therefore, a large dosage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0d4c41cbfc30ffc15571fe67ade33c8
https://doi.org/10.1021/acs.molpharmaceut.0c00471
https://doi.org/10.1021/acs.molpharmaceut.0c00471
Autor:
Daniel T. Regan, Deanna M. Mudie, Molly S. Adam, Kimberly B. Shepard, John M. Baumann, Michael M. Morgen, David T. Vodak
Publikováno v:
Powder Technology. 362:221-230
Spray drying is one of the most broadly applicable and widely used methods of producing amorphous solid dispersions (ASDs). ASDs can improve the oral absorption of poorly water-soluble active pharmaceutical ingredients. Eudragit L100 is an appealing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce9819c7e3edb38ff40f1f0b6a2f1b58
https://doi.org/10.1016/j.powtec.2019.12.013
https://doi.org/10.1016/j.powtec.2019.12.013
Autor:
Jesus A. Rosales, Michael M. Morgen, David T. Vodak, Aaron M. Stewart, Deanna M. Mudie, Molly S. Adam
Publikováno v:
Pharmaceutics
Pharmaceutics; Volume 13; Issue 8; Pages: 1257
Pharmaceutics, Vol 13, Iss 1257, p 1257 (2021)
Pharmaceutics; Volume 13; Issue 8; Pages: 1257
Pharmaceutics, Vol 13, Iss 1257, p 1257 (2021)
Amorphous solid dispersion (ASD) dosage forms can improve the oral bioavailability of poorly water-soluble drugs, enabling the commercialization of new chemical entities and improving the efficacy and patient compliance of existing drugs. However, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f54b650c9ae45f98ecc2ea081f901673
https://pubmed.ncbi.nlm.nih.gov/34959483
https://pubmed.ncbi.nlm.nih.gov/34959483
Autor:
Deanna M, Mudie, Aaron M, Stewart, Nishant, Biswas, Timothy J, Brodeur, Kimberly B, Shepard, Adam, Smith, Michael M, Morgen, John M, Baumann, David T, Vodak
Publikováno v:
Molecular pharmaceutics. 17(12)
Amorphous solid dispersions (ASDs) can increase the bioavailability of drugs with poor aqueous solubility. However, concentration-sustaining dispersion polymers (CSPs) incorporated in ASDs can result in low drug loading and, therefore, a large dosage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a0dd39827cda281513d0be2ae2937550
https://pubmed.ncbi.nlm.nih.gov/32835489
https://pubmed.ncbi.nlm.nih.gov/32835489